Zosano Pharma Corporation (ZSAN)

US98979H3012 - Common Stock

0.5576  +0.04 (+7.23%)

After market: 0.5459 -0.01 (-2.1%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
220K790K
259.09%		204K
EBITDA
YoY % growth
-36.52M
-7.07%		-31.33M
14.21%		-29.78M
4.95%		-13.295M
EBIT
YoY % growth
-37.2M
-6.68%		-32.76M
11.94%		-31.53M
3.75%		-15.311M
Operating Margin
N/A-14,890.91%-3,991.14%-7,505.50%
EPS
YoY % growth
-2.34-0.57
75.64%		-6.73
-1,080.70%		-0.09

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 22 Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.02
Revenue
Q2Q % growth		102K
EBITDA
Q2Q % growth		-3.138M
EBIT
Q2Q % growth		-3.635M

Recent Earnings VS Estimates Surprises ()
PeriodReportedEstimateDifferenceSurprise
Q1 2022
Q2Q % growth		 -1.76
-2,100.00%		-1.790.031.40%
Q4 2021
Q2Q % growth		 -2.10
-2,525.00%		-1.61-0.49-30.72%
Q3 2021
Q2Q % growth		 -2.45
-2,127.27%		-2.740.2910.49%
Q2 2021
Q2Q % growth		 -2.10
-1,400.00%		-2.740.6423.28%
Recent Revenue VS Estimates Surprises

Reported revenue can not be compared with estimates as they are in different currencies. Reported data is in USD, while estimates are .

PeriodReportedEstimateDifferenceSurprise
Q1 2022
Q2Q % growth		 130K
-50.00%		102K28K27.45%
Q4 2021
Q2Q % growth		 90K
-59.09%		1.53M-1.44M-94.12%
Q3 2021
Q2Q % growth		 250K
∞%		265.2K-15.2K-5.73%
Q2 2021
Q2Q % growth		 190K
∞%		261.803K-71.803K-27.43%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A